GET DAILY SIGNALSLiquidia (LQDA) Delivers Strong Q3 Revenue Growth Despite Major Settlement
Key Takeaways
- Third quarter 2026 total revenue reached $225.3 million, up sharply from $54.34 million in the same period a year earlier, driven almost entirely by YUTREPIA.
- YUTREPIA net product sales totaled roughly $222.7 million, up about 31% sequentially from the second quarter of 2026.
- GAAP net loss was $236.3 million, or $2.64 per share, reflecting a roughly $389.7 million litigation settlement charge tied to United Therapeutics.
- Non-GAAP adjusted EBITDA was approximately $140.5 million, the fifth consecutive quarter of sequential improvement.
- A global settlement narrows YUTREPIA's approved use to PAH and commits about $380.7 million in cash payments through April 2027.
- Cash and cash equivalents ended the quarter at approximately $396 million, before settlement-related outlays are fully reflected.
Earnings Context and Why It Matters
Liquidia Corporation is a biopharmaceutical company focused on rare cardiopulmonary conditions, led by its inhaled treprostinil product YUTREPIA. Approved by the FDA in May 2025 and launched commercially in June 2025, YUTREPIA has rapidly become the company's dominant revenue driver. The third quarter of 2026 is significant because it captures a maturing commercial launch while also being the first report after a major patent ruling and global settlement with United Therapeutics. For investors, the quarter tests whether strong sales momentum can coexist with a narrower label and a substantial cash commitment.
Breaking Down the Reported Results
Liquidia reported total revenue of $225.3 million for the third quarter ended September 30, 2026, compared with $54.34 million a year earlier. YUTREPIA net product sales were approximately $222.7 million, up about 31% sequentially. Revenue came in ahead of consensus expectations, while reported GAAP results were dominated by a one-time charge.
The company recorded a GAAP net loss of $236.3 million, or $2.64 per share, versus a net loss of $3.53 million, or $0.04 per share, in the prior-year quarter. The swing was driven by a roughly $389.7 million litigation settlement charge. Excluding that item, non-GAAP adjusted EBITDA was approximately $140.5 million, the fifth straight quarter of sequential growth, with adjusted earnings around $0.80 per share.
Management also disclosed that the previously repeated $1 billion 2027 revenue target has been retired, with a clearer guidance update now expected in January 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Liquidia shares have been volatile around this earnings cycle. After an October 1, 2026 federal court ruling that certain patent claims covering inhaled treprostinil for PH-ILD were valid and infringed, the stock fell to a 52-week low of $22.31. It subsequently rebounded roughly 115% from that low as the October 13 global settlement with United Therapeutics removed the worst-case disruption scenario.
Heading into the report, sentiment had cooled from mildly positive to roughly neutral, reflecting the settlement's trade-offs: YUTREPIA remains on the market without interruption, but its label is now limited to PAH and the company has committed significant cash. Post-report, investors are weighing strong commercial execution and expanding adjusted EBITDA margins against the reduced size of the addressable market.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst is the January 2027 guidance update, which will clarify how much growth management expects under the PAH-only label. Investors will also watch how the roughly $380.7 million settlement liability, payable in installments through April 2027, affects the balance sheet and operating flexibility.
Commercially, key metrics to monitor include YUTREPIA patient additions, payer access, and whether the company can continue converting referrals into prescriptions at the high rates seen during launch. Adjusted EBITDA margin expansion will signal whether the business can sustain profitability while absorbing the settlement costs.
On the pipeline side, the next-generation inhaled therapy L606 represents a longer-term growth lever, and its development costs are a factor in research and development spending. Industry competition in the prostacyclin space also remains a watch item. Overall, the story has shifted from pure launch momentum to execution within a narrower but still substantial commercial opportunity. From what I see, this is important because it sets the stage for how the company navigates its more focused opportunity set.
Using Tickeron Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals have been helpful for tracking momentum shifts in names like this one after major events. I also ran a quick scan with the AI Pattern Search Engine to look at historical reactions to similar settlements in the sector. These resources let me cross-check the numbers against broader market patterns without spending hours on manual work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LQDA's RSI Oscillator recovers from oversold territory
The RSI Oscillator for LQDA moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LQDA as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.
LQDA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +15.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 280 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 200 of 247 cases where LQDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 68 cases where LQDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
The 50-day moving average for LQDA moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
LQDA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.369) is normal, around the industry mean (6.379). P/E Ratio (28.101) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of particle-based vaccines and therapeutics for prevention and treatment of human disease
Industry PharmaceuticalsGeneric
Advertisement